ImmunityBio Inc. Stock
€1.87
Your prediction
ImmunityBio Inc. Stock
Pros and Cons of ImmunityBio Inc. in the next few years
Pros
Cons
Performance of ImmunityBio Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| ImmunityBio Inc. | -3.690% | -5.174% | 1.438% | -37.642% | -32.485% | -67.988% | -81.654% |
| Ardelyx Inc. | -0.240% | 1.781% | -5.023% | -0.906% | 1.309% | 196.755% | -8.512% |
| Krystal Biotech | 0.050% | 10.231% | 19.886% | 20.057% | 38.042% | 195.915% | - |
| Evolus Inc | 2.590% | 6.250% | -0.833% | -47.807% | -43.333% | -15.000% | 97.020% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.When diving into the financials of ImmunityBio, a company operating in the Biotechnology & Medical Research sector, the overall impression is that of a company grappling with significant challenges. Key metrics such as earnings, profitability, and valuation ratios suggest a period of struggle, which may be indicative of a firm still in the development stages of its products. This analysis aims to break down both the merits and downfalls of the current financial landscape to better understand ImmunityBio's potential trajectory.
Market Capitalization
Revenue Generation
Comments
News
A Fresh $16 Million Bet on ImmunityBio: What Investors Should Know
Heights Capital Management recently established a new position in ImmunityBio (NASDAQ:IBRX), buying 6,565,709 shares valued at approximately $16.15 million.
Heights Capital Management disclosed a
IBRX Sales Soar 2,540%
ImmunityBio (NASDAQ:IBRX), a commercial-stage biotechnology company, released its second-quarter results on August 5, 2025. The main headline: revenue (GAAP) jumped to $26.4 million, soundly beating